Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Crossref DOI link: https://doi.org/10.1007/s40273-016-0436-6
Published Online: 2016-08-01
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rafia, Rachid http://orcid.org/0000-0002-6914-1990
Scope, Alison
Harnan, Sue
Stevens, John W.
Stevenson, Matt
Lobo, Alan
Funding for this research was provided by:
Health Technology Assessment Programme (13/128/01)
License valid from 2016-08-01